08/13/2025
4:40 PM | Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
| Form SCHEDULE 13G | |
08/06/2025
6:32 AM | Arbutus Biopharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/06/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/23/2025
3:08 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2025
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/23/2025
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/21/2025
1:11 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/15/2025
3:27 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/01/2025
4:47 PM | Arbutus Biopharma (Issuer)
Nguyen Tuan (Reporting)
| Form 4/A | |
Get the Latest News and Ratings for ABUS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. |
03/31/2025
8:42 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/27/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/27/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/24/2025
8:19 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/20/2025
3:08 PM | Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:10 PM | Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2025
8:34 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/07/2025
1:59 PM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/06/2025
3:07 PM | Arbutus Biopharma (Issuer)
Gline Matthew (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:08 PM | Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:10 PM | Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:11 PM | Arbutus Biopharma (Issuer)
Bishop Joseph E (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:13 PM | Arbutus Biopharma (Issuer)
Hasija Anuj (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/03/2025
8:24 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/25/2025
6:05 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/25/2025
6:19 AM | Arbutus Biopharma (Subject)
Roivant Sciences Ltd. (Filed by)
Roivant Sciences Ltd. (Filed by)
| Form SCHEDULE 13D/A | |
02/21/2025
8:00 AM | Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
| Form SCHEDULE 13D/A | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/04/2025
7:34 PM | Arbutus Biopharma (Subject)
Naftzger J. Christopher (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:36 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:38 PM | Arbutus Biopharma (Subject)
Sims Karen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:39 PM | Arbutus Biopharma (Subject)
HASTINGS DAVID C (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/03/2025
2:26 PM | Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
11:15 PM | Arbutus Biopharma (Filer)
| Form EFFECT | |
11/15/2024
10:03 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
7:41 AM | Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
| Form SC 13G/A | |
Trump’s national nightmare is here (Ad) Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II.
They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. Watch the National Emergency broadcast here |
11/06/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/15/2024
7:26 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/11/2024
3:07 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
MarketBeat All Access